GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Blood, American Society of Hematology, Vol. 108, No. 11 ( 2006-11-01), p. 2485-2485
    Abstract: Cladribine (2-chlorodeoxyadenosine, 2-CdA) has dramatically improved prognosis of hairy cell leukemia (HCL), though the 2-CdA treatment-associated life-threatening infections may shorten potentially long-term survival of HCL patients. In search of optimal mode of 2-CdA administration in HCL, we compared the standard 5-day 2-CdA protocol with a novel weekly 2-CdA schedule that was suggested to be equally effective, but less toxic. Between the 1st January 1998 and the 31st September 2005, 132 patients with previously untreated, active HCL from 14 hematology centers were included to the study. Patients were randomly assigned to receive 2-CdA at 0.12 mg/kg in 2-hour intravenous infusion for 5 days (64 patients), or 2-CdA at 0.12 mg/kg in 2-hour intravenous infusion once a week for 6 weeks (62 patients). The response to chemotherapy was evaluated according to the NCI guidelines and treatment-related toxicity was recorded using standard WHO criteria. One hundred and sixteen patients were included in the final analysis of the trial. Comparison of the treatment response between daily and weekly 2-CdA protocols showed similar complete remission rate (76% and 72%, p=0.86) as well as similar overall response rate (95% and 91%, p=0.41). Survival analysis did not show significant difference between the study arms. Median progression-free survival equaled 4.3 years (95%CI = 3.3 – 5.2) and 5.1 years (95%CI = 4.7 – 5.6) (p=0.28) for patients treated with daily and weekly schedule, respectively. The estimated 6.5 year overall survival was 91% for daily and 88% for weekly 2-CdA protocol, p = 0.40. Interestingly, the analysis of adverse events did not confirm lower toxicity of the weekly 2-CdA schedule. Of special interest, there were no significant differences between daily and weekly protocol in the rate of treatment-related neutropenia (47% vs. 47%, p=0.97), the rate of grade 3/4 infections (18% vs. 26%, p=0.28), or the rate of 2-CdA-related septic deaths (2% vs. 1%, p=0.64). In conclusion, the results of our randomized study indicate that HCL treatment based on weekly 2-CdA infusions for 6 weeks is equally effective, but not safer than standard 5-day 2-CdA protocol.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2006
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: The Lancet, Elsevier BV, ( 2023-9)
    Type of Medium: Online Resource
    ISSN: 0140-6736
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2023
    detail.hit.zdb_id: 2067452-1
    detail.hit.zdb_id: 3306-6
    detail.hit.zdb_id: 1476593-7
    SSG: 5,21
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Blood, American Society of Hematology, Vol. 128, No. 22 ( 2016-12-02), p. 1685-1685
    Abstract: Background One of the potential mechanisms responsible for leukemic cells evading cytotoxic T lymphocytes might be the pathway of programmed death-1 receptor (PD-1). PD-1 and its ligand PD-L1 play a key role in tumor immune escape and the formation of tumor microenvironment, promoting tumor development. Aims As PD-L1 expression was broadly described in many types of human cancer cells including AML, we were focused on PD-1 expression, which until now was mostly characterized for T cells, where it inhibits proliferation and cytotoxic capabilities. Recently, Wang et al. described PD-L1 expression regulation through miR-34a molecules in AML patients. Overexpression of miR-34a blocked PD-L1 and reduced its surface expression. Moreover, Cortez et al. for the first time identified novel, complete mechanism of PD-L1 regulation by p53 via miR-34a in non-small cell lung cancer (NSCLC). In this study, our comprehensive analyses of PD-1, PD-L1, TP53and miR-34a expression in AML patients shed new light on the complex regulation of PD-1/PD-L1 axis during development of this disease. Methods We performed analysis of TP53, PD-1, PD-L1 and miR-34a expression in 197 AML patients available from The Cancer Genome Atlas (TCGA) database. Moreover, we assessed mRNA expression of TP53 and PD-1 in independent cohort of 54 primary AML patient samples using qRT-PCR method. We also characterized several SNPs for PD-1that demonstrate relevant associations with a higher risk of developing autoimmune diseases: PD-1.1 (rs36084323), PD-1.3 (rs11568821), PD-1.5 (rs2227981), PD-1.6 (rs10204525), PD -1.7 (rs41386349), PD-1.9 (rs2227982) in 54 AML, 64 MDS and 100 HVs samples. Results TCGA data analysis showed higher expression of PD-L1 in the AML group with low expression of TP53 (p=0.008). In contrast, PD-L1 expression was elevated in the group with TP53 mutations compared to unmutated TP53 (p 〈 0.001).We also found a negative correlation of miR-34a and PD-L1 expression (r=-0.2; p=0.005), while there were no differences in PD-L1 expression between groups with or without following mutations: IDH1, TET2, RUNX1, NRAS, CEBPA, PTPN11, KIT, KRAS, FLT3, DNMT3, NPM1 and IDH2. The highest expression of PD-L1 was found in the poor prognosis group according to cytogenetic risk and molecular risk markers. We also observed an association between the expression level of PD-L1 and the number of recurrent mutations present in an AML case. Patients with more than 4 recurrent mutations were characterized with higher expression of PD-L1 compared to the group of patients with 0-3 recurrent mutations (p=0.01). Next, we observed significant differences in PD-1 expression in the group of 54 AML patients compared to HVs (p 〈 0.001), and there were differences in the PD-1expression level regarding the PD-1. 5 polymorphism (p=0.07). Moreover, analysis of the PD-1. 3 polymorphism in HVs and MDS revealed that genotype GG was associated with nearly fivefold lower risk of disease (OR=4.93, p=0.009). We observed significant differences in OS in AML patients in case of presence of certain genotypes of PD-1. 6. Genotype AA was significant associated with higher risk of shorter OS compared to the rest of the genotypes (58 vs 333 days, HR=35; p=0.02). Conclusions Our analyses indicate that p53 might specifically modulate the tumor immune response by regulating PD-L1 via miR-34a which directly binds to the PD-L13'-UTR and blocks its expression. Moreover, we found that high PD-L1 expression is associated with the higher numbers of recurrent mutations as well as poor cytogenetic and molecular risk groups. We found significant differences in PD-1expression in AML patients compared to HVs that further support a deregulation of a signal transduction through the PD-1/PD-1L axis in AML. While our SNP analysis in AML patients suggested a prognostic impact of PD-1. 6 polymorphism, further studies are warranted to evaluate the impact of the PD-1/PD-L1 axis in AML. This work was supported by National Centre for Science Grant HARMONIA (UMO-2013/10/M/NZ5/00313). Disclosures Grzasko: Janssen: Honoraria; Munipharma: Honoraria; Celgene: Honoraria.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2016
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Blood, American Society of Hematology, Vol. 114, No. 22 ( 2009-11-20), p. 4848-4848
    Abstract: Abstract 4848 Background Myelodysplastic syndrome(MDS) belong to the most common hematological diseases however epidemiological data on MDS are sparse. Until 2008 there were no data about epidemiology of MDS in Poland. Methods From 03.2008-05.2009 we have registered 966 patients in Polish MDS Registry. We have included only alive patients of various time of diagnosis. Patients from 22 centers were diagnosed according to WHO 2001 criteria. Results There were 508(53%)males and 458(47%) females. Median age at diagnosis was 70(range 19-99). Under 50 were 83(9%) cases with preponderance of females- 51 cases( males 32cases), between 50-70 there were 353(41%) cases, half of the patients-432(50%) were above 70( 247 males and 185 females).Prior chemotherapy and/or radiotherapy had 37((3,8%) patients. Distribution of MDS subtypes was as follows: RA-170(20%) cases, RARS-58(7%), RCMD-244(28%), RCMD-RS-18(2%), RAEB-1-120(14%), RAEB-2-169(19,5%), 5q- -40(4,6%), MDS-U-44(5%).In 103(10%) subtype was not done. Karyotype was available in 276(28%) cases. Cytogenetic risk groups were: low risk-182(68%), intermediate-52(20%) and high risk-33(12%). The most frequent cytogenetic results were: normal karyotype 44%, isolated 5q deletion 19%, complex karyotype 6%, 5q deletion + another one change 3% and 5q deletion with at least 2 changes 3%. According to IPSS risk groups low risk was found in 61( 22%) of cases, intermediate-1 -130(48%), intermediate-2-47(17%) and high risk in 31(11,5%). Median values of Hb was 9,1 g/dL, plts 129 G/L, ANC 1,7 G/L. RBC transfusion dependent were 429(44%) patients and platelet transfusion dependent were 100( 11%) pts. At least 2 U/month RBC transfusion requirement was 140(14%) patients. Serum ferritin level was assessed in 530 cases-171 of them( 32%) had higher than 1000μg/L level. Conclusions We have observed predominance of females among MDS patients under 50. Half of the patients had RA or RCMD subtype. Isolated 5 q deletion was the most frequent cytogenetic abnormality. Forty four percentage of patients was RBC transfusion dependant. Serum ferritin level was significantly elevated in 32% of assessed patients at the moment of MDS diagnosis. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2009
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    Online Resource
    Online Resource
    Walter de Gruyter GmbH ; 2016
    In:  Postępy Higieny i Medycyny Doświadczalnej Vol. 70 ( 2016-1-4), p. 811-819
    In: Postępy Higieny i Medycyny Doświadczalnej, Walter de Gruyter GmbH, Vol. 70 ( 2016-1-4), p. 811-819
    Type of Medium: Online Resource
    ISSN: 1732-2693
    Language: Unknown
    Publisher: Walter de Gruyter GmbH
    Publication Date: 2016
    detail.hit.zdb_id: 2150116-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Blood, American Society of Hematology, Vol. 109, No. 9 ( 2007-05-01), p. 3672-3675
    Abstract: Cladribine (2-chlorodeoxyadenosine, 2-CdA) treatment-associated infections may shorten potentially long-term survival in hairy cell leukemia (HCL). In search of the optimal mode of 2-CdA administration, 132 patients with untreated HCL were randomized to receive either standard 5-day 2-CdA protocol or a novel schedule of 6 weekly 2-CdA infusions suggested to be less toxic. Analysis of treatment response confirmed similar complete remission rates, overall response rates, progression-free survival, and overall survival in both 2-CdA protocols. However, we did not observe lower toxicity in the weekly schedule. Of special interest, no significant differences were found in the rate of grade 3/4 infections (18% for daily and 26% for weekly protocol, difference −8.2%; 95% confidence interval [CI] −23.2% to 6.9%; P = .28) and the rate of septic deaths (3% for daily and 2% for weekly protocol, difference 1.4%; 95% CI −4.3% to 7.0%; P = .64). In conclusion, HCL treatment with weekly 2-CdA infusions is equally effective but no safer than the standard 5-day 2-CdA protocol.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2007
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: The Lancet Haematology, Elsevier BV, Vol. 7, No. 3 ( 2020-03), p. e196-e208
    Type of Medium: Online Resource
    ISSN: 2352-3026
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2020
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Blood, American Society of Hematology, Vol. 104, No. 11 ( 2004-11-16), p. 4819-4819
    Abstract: Previously, we reported a study on efficacy and toxicity of cladribine (2-CdA) + prednisone (P) compared with chlorambucil (Chl) + P in previously untreated patients with progressive or symptomatic chronic lymphocytic leukemia (CLL) in a randomized multicenter trial (Blood2000, 96, 2723). Of 229 patients enrolled, 126 received 2-CdA+P and 103 received Chl+P. Here, we present the long-term follow-up and the results of subsequent treatment in refractory or relapsed patients. Patients with non responsive (NR) disease or with progression after 3 courses of 2-CdA + P or Chl+P or who relapsed earlier then 12 months after completing the treatment were switched to an alternative arm. Patients who relapsed later than 12 months from first remission (late relapse) were retreated with the same schedule that induced previous response. In 50 patients, non-responsive or with early relapse, treated originally with Chl+P who received 2-CdA+P as second line, complete response (CR) was achieved in 12 (24%) and overall response (OR) in 32 (64%). Twenty eight patients originally treated with 2-CdA+P received Chl+P and CR and OR was obtained in 1 (3,6%) and in 6 (21.4%), respectively (p=0.002 for both arms). Thirty three patients with late relapse were retreated with 2-CdA+P and 19 patients were retreated with Chl+P. OR (CR) was 54.6% (6.1%) and 47.4% (15.8%), respectively (p=0.34). The third line treatment was CHOP in both arms. Twenty seven patients from 2-CdA+P group and 37 patients from Chl+P group were treated with CHOP and only one patient responded. Median survival was 3.3 and 3.75 years, respectively (p=0.63). Secondary neoplasms were observed in 8 (6.4%) patients treated with 2-CdA+P and in 4 (3.9%) treated with Chl+P as first line treatment (p=0.6). Death rates have been similar in patients treated originally with 2-CdA+P 82 (64.6%) and Chl+P 69 (66.4%) (p=0.8). In conclusion, cladribine is significantly more effective as a second line treatment than chlorambucil. Both agents are similarly effective in retreatment of late relapsed patients. CHOP is of no value in patients previously treated with 2-CdA + P and with Chl + P. There is no significant difference in median survival of patients treated initially with Chl + P and 2-CdA + P.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2004
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Blood, American Society of Hematology, Vol. 126, No. 23 ( 2015-12-03), p. 2590-2590
    Abstract: Background The relevance of differential splicing in human cancer is an evolving area of cancer biology. The recent findings of frequent mutations of the splicing pathways in MDS provide insight into the mechanism of alternative splicing, which has been long associated with the development of cancer. The genome-wide microarray analysis using Exon arrays discovered significantly differentially spliced genes in AML. Moreover, the AML specific "splicing profile" was normalized in remission and reappears with patient relapse, thereby supporting a role of deregulated splice variants in the process of leukemogenesis. A close cytogenetic and molecular analogy between de novo MDS and AML of elderly people suggests a common pathogenic mechanism for these conditions. Recent clinical and biological studies indicate that MDS and AML could be considered as part of the same continuous disease spectrum rather than as distinct disorders. Recently, we found that high expression of the NPM1 splice variant R2 may provide prognostic value for CN-AML patients. Assuming the common origin of MDS and AML we aimed to characterize the NPM1 R2 splice variant expression as well as the influence of R2 expression on NPM1 localization in groups with MDS, sAML and AML patients. Moreover, NPM1 stabilizes the ARF and interacts with the tumor suppressor p53, regulates the increase in stability and transcriptional activation of p53, thus contributing to modulating growth-suppressive pathways. Therefore, we characterized expression pattern of ARF, MDM2, TP53 genes with additional downstream molecules (p21, miR-34a) in AML, s-AML and MDS patients. Methods Since we found prognostic significance of the expression level of R2 for the AML cohort of patients, therefore we decided to evaluate its significance for MDS and sAML cases. For 61 samples (25 AML, 30 MDS and 6 samples with sAML) qRT-PCR was performed. Expression level of NPM1 R2 was assessed. To investigate whether R2 might disrupt localization of the NPM1 wild type protein, immunohistochemistry analysis for NPM1 in 23 AML bone marrow smears was performed. As NPM1 contributes to regulation of ARF-MDM2-p53-p21 signaling pathway proteins we assessed if high or low expression of its splice variant R2 might have influence on expression pattern of these transcripts. Results The expression of R2 was significantly higher in AML, s-AML and MDS groups compared to HVs (median 0.022 vs 0.005, p 〈 0.001, 0.022 vs 0.005, p 〈 0.001 and 0.015 vs 0.005, p 〈 0.001, respectively). The IHC stainings for AML samples revealed that in cases with high R2 expression we were able to determine a cytoplasmic localization of NPM1 even in the absence of its concomitant mutation. Therefore, we provide further evidence that the cytoplasmic localization of NPM1 might depend not only on its mutational status, but might be influenced by the distribution of its splice variants. We performed ARF, MDM2, TP53 and p21 mRNA expression analysis in AML, s-AML, MDS and HV groups and found significant differences between these groups (Figure 1A-D). We also analyzed the expression of ARF, MDM2, TP53 and p21 in groups with high or low R2 expression. We found elevated expression of MDM2 and TP53 in groups with high R2 expression in comparison to groups with low R2 expression in AML patients (median 0.007 vs 0.005, p=0.03 and 0.009 vs 0.005, p 〈 0.001, respectively), (Figure 1F, G). In case of MDS patients we also found elevated expression of MDM2 and TP53 in groups with high R2 expression compared to groups with low R2 expression (median 0.005 vs 0.003, p=0.033 and 0.006 vs 0.003, p=0.001, respectively), (Figure 1J, K). Conclusions In our study we found that the expression levels of R2 were elevated in AML, sAML and MDS groups compared to HVs suggesting that R2 might play some role in the process of the tumorigenesis not only in AML cases but also in early stages of development of this disease. As the NPM1 R2 splice variant represents a truncated form of NPM1 gene this isoform mostly localizes in the nucleoplasm, and thus might also have a biological impact in the malignant cells. We found elevated expression of MDM2 and TP53 in groups with high R2 expression compared to groups with low R2 expression in AML as well as MDS patients. In summary, the expression of NPM1 R2 might be of biological importance for AML as well as for sAML and MDS patients. This work was supported by National Centre for Science Grant HARMONIA (UMO-2013/10/M/NZ5/00313). Figure 1. Figure 1. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2015
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Blood, American Society of Hematology, Vol. 128, No. 22 ( 2016-12-02), p. 2878-2878
    Abstract: Background Acute myelogenous leukemia (AML) represents a heterogeneous group of myeloid malignancies harboring different chromosomal abnormalities, gene mutations, and epigenetic modifications. Recent clinical and biological studies indicate that myelodysplastic syndromes (MDS) and AML could be considered as part of the same continuous disease spectrum rather than as distinct disorders. NPM1 is a multifunctional protein involved in both biological and pathological processes controlling development, cell proliferation, ribosome biogenesis, transformation and genomic stability. It interacts with many cellular proteins, including ARF and the tumor suppressor p53. Recently, we found that high expression of the NPM1 splice variant R2, which encodes a truncated form of NPM1, may provide prognostic value for CN-AML patients. Aims Therefore, our aim was evaluation of NPM1 R2 splice variant significance for MDS and sAML cases, as well as assignment if different expression levels of R2 might have influence on the expression pattern of each of the components of the ARF-MDM2-p53-p21 signaling pathway and additional downstream molecules (miR-34a, miR-34b and miR-34c). In order to determine the impact of NPM1 R2 on NPM1 localization and to compare it with the NPM1mut effect, transfection analyses and IHC stainings were performed. Methods NPM1 R2, CDKN2A (encoding ARF), MDM2, TP53 and CDKN1A(encoding p21) genes expression levels were assessed for 128 samples (58 AML, 62 MDS and 8 sAML) using qRT-PCR. Additionally, expression level of miR-34a (n=29), miR-34b (n=20) and miR-34c (n=20) was measured in CD33+ cells derived from AML patient samples. WI-38 fibroblasts and HEK-293 cells were transfected with constructs containing eGFP-tagged NPM1-R2, NPM1-mut and NPM1-wt under a cytomegalovirus promoter, stained and visualized with confocal microscope. Immunochemistry analysis was performed for NPM1 in 23 AML bone marrow smears. Results NPM1 R2 expression levels differed between AML, sAML, MDS and healthy volunteers (HV) groups and were significantly higher in AML, sAML and MDS groups compared to HVs (median 0.023 vs 0.005, p 〈 0.001, 0.025 vs 0.005, p 〈 0.001 and 0.017 vs 0.005, p 〈 0.001, respectively). CDKN2A, MDM2, TP53 and CDKN1A expression analysis in these sample groups showed also significant differences. Expression of TP53 was elevated in groups with high R2 expression in comparison to groups with low R2 expression in AML and MDS patients (median 0.01 vs 0.005, p 〈 0.001 and 0.007 vs 0.004, p 〈 0.001, respectively). Moreover, we found strong positive correlation of R2 expression with TP53 expression in AML (r=0.77, p 〈 0.001) and MDS (r=0.68, p 〈 0.001). We observed elevated expression of miR-34c in HVs group compared to AML (0.11 vs 0.07, p 〈 0,001) and trend to decreased expression of miR-34a in AML in comparison with HVs. No differences were found in miR-34a, miR-34b and miR-34c expression between groups with high or low R2 expression. Transfection analyses showed various localization of each eGFP-tagged NPM1 forms. NPM1-wt localized mainly in nucleoli, NPM1-R2 was detected in the nucleoplasm and nucleoli, whereas eGFP-NPM1-mut displayed cytoplasmic localization. However, the IHC stainings for AML samples revealed that in cases with high R2 expression we were able to determine a cytoplasmic localization of NPM1 even in the absence of its concomitant mutation. Conclusions The elevated level of NPM1 R2 splice variant in AML, sAML and MDS groups versus HVs suggests that R2 might play some role in neoplasia process also in early stages of this hematological malignancy. Transfection analyses established that NPM1 R2 mostly localizes in the nucleoplasm, where it might interact with other proteins e.g. ARF and p53. Nucleolar localization of this NPM1 form might be determined both by lack of nucleolar localization signal present in the wt form of NPM1 and nuclear export signal occurring in mutated NPM1. Moreover, strong positive correlation between R2 and TP53 expression was found in AML and MDS groups suggesting biological link between these transcripts. In summary, the expression of NPM1 R2 might be of biological importance for AML as well as for transformation of MDS into sAML. This work was supported by National Centre for Science Grant HARMONIA (UMO-2013/10/M/NZ5/00313). Disclosures Grzasko: Celgene: Honoraria; Munipharma: Honoraria; Janssen: Honoraria.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2016
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...